BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu Q, Dai W, Ji J, Wu L, Feng J, Li J, Zheng Y, Li Y, Cheng Z, Zhang J, Wu J, Xu X, Guo C. Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c‐myc/hexokinase 2 pathway. J Cellular Molecular Medi. [DOI: 10.1111/jcmm.17322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu Y, Hao X, Ren Y, Xu Q, Liu X, Song S, Wang Y. Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma. Front Oncol 2022;12:1063423. [PMID: 36686771 DOI: 10.3389/fonc.2022.1063423] [Reference Citation Analysis]
2 Chuanbing Z, Zhengle Z, Ruili D, Kongfan Z, Jing T. Genes Modulating Butyrate Metabolism for Assessing Clinical Prognosis and Responses to Systematic Therapies in Hepatocellular Carcinoma. Biomolecules 2022;13. [PMID: 36671437 DOI: 10.3390/biom13010052] [Reference Citation Analysis]
3 Li R, Mei S, Ding Q, Wang Q, Yu L, Zi F. A pan-cancer analysis of the role of hexokinase II (HK2) in human tumors. Sci Rep 2022;12:18807. [PMID: 36335239 DOI: 10.1038/s41598-022-23598-8] [Reference Citation Analysis]
4 Wang X, Wu L, Ji H, Liu Q, Deng S, Dou Q, Ai L, Pan W, Zhang H. A novel cuproptosis-related prognostic signature and potential value in HCC immunotherapy. Front Mol Biosci 2022;9:1001788. [DOI: 10.3389/fmolb.2022.1001788] [Reference Citation Analysis]
5 Deng S, Chen B, Huo J, Liu X. Therapeutic potential of NR4A1 in cancer: Focus on metabolism. Front Oncol 2022;12:972984. [DOI: 10.3389/fonc.2022.972984] [Reference Citation Analysis]